| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 54 | 2020 | 476 | 4.810 |
Why?
|
| Robotics | 44 | 2015 | 269 | 4.460 |
Why?
|
| Prostatic Neoplasms | 55 | 2021 | 1768 | 3.100 |
Why?
|
| Laparoscopy | 35 | 2020 | 771 | 2.770 |
Why?
|
| Erectile Dysfunction | 8 | 2010 | 75 | 0.780 |
Why?
|
| Urology | 4 | 2020 | 117 | 0.730 |
Why?
|
| Prostate | 10 | 2015 | 393 | 0.710 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 302 | 0.620 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 220 | 0.600 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 46 | 0.560 |
Why?
|
| Urinary Incontinence | 6 | 2012 | 213 | 0.560 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 98 | 0.540 |
Why?
|
| Middle Aged | 57 | 2020 | 25826 | 0.520 |
Why?
|
| Head-Down Tilt | 1 | 2015 | 5 | 0.510 |
Why?
|
| Adenocarcinoma | 7 | 2021 | 1194 | 0.510 |
Why?
|
| Male | 77 | 2021 | 42191 | 0.500 |
Why?
|
| Ear Diseases | 1 | 2015 | 20 | 0.500 |
Why?
|
| Urinary Bladder, Neurogenic | 3 | 2011 | 25 | 0.500 |
Why?
|
| Clinical Clerkship | 2 | 2007 | 118 | 0.500 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 115 | 0.490 |
Why?
|
| Hematoma | 1 | 2015 | 108 | 0.480 |
Why?
|
| Urinary Catheters | 1 | 2014 | 6 | 0.470 |
Why?
|
| Aged | 47 | 2021 | 19044 | 0.470 |
Why?
|
| Urinary Catheterization | 1 | 2014 | 36 | 0.460 |
Why?
|
| Drainage | 1 | 2014 | 162 | 0.430 |
Why?
|
| Device Removal | 1 | 2014 | 167 | 0.410 |
Why?
|
| Urinary Diversion | 2 | 2010 | 42 | 0.400 |
Why?
|
| Curriculum | 2 | 2007 | 567 | 0.400 |
Why?
|
| Prospective Studies | 20 | 2014 | 4265 | 0.390 |
Why?
|
| Sural Nerve | 2 | 2008 | 19 | 0.380 |
Why?
|
| Neoplasm Staging | 16 | 2016 | 1999 | 0.380 |
Why?
|
| Laparoscopes | 2 | 2008 | 15 | 0.380 |
Why?
|
| Seminal Vesicles | 4 | 2021 | 39 | 0.380 |
Why?
|
| Humans | 84 | 2021 | 88946 | 0.370 |
Why?
|
| Treatment Outcome | 25 | 2020 | 8188 | 0.340 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 21 | 0.330 |
Why?
|
| Suture Techniques | 6 | 2010 | 140 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 103 | 0.310 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 3655 | 0.310 |
Why?
|
| Urination Disorders | 4 | 2008 | 50 | 0.300 |
Why?
|
| Preoperative Care | 6 | 2013 | 396 | 0.300 |
Why?
|
| Retrospective Studies | 18 | 2020 | 8990 | 0.300 |
Why?
|
| Teaching Materials | 1 | 2007 | 14 | 0.300 |
Why?
|
| Learning | 2 | 2007 | 284 | 0.290 |
Why?
|
| Equipment Failure | 1 | 2007 | 121 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2008 | 394 | 0.270 |
Why?
|
| Educational Measurement | 1 | 2007 | 231 | 0.260 |
Why?
|
| Postoperative Care | 5 | 2014 | 229 | 0.250 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 233 | 0.220 |
Why?
|
| Urethra | 2 | 2006 | 115 | 0.220 |
Why?
|
| Adult | 29 | 2016 | 26473 | 0.220 |
Why?
|
| Urologic Surgical Procedures | 2 | 2017 | 147 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 1361 | 0.210 |
Why?
|
| Postoperative Complications | 11 | 2011 | 2273 | 0.210 |
Why?
|
| Carcinoma, Giant Cell | 1 | 2002 | 2 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2012 | 987 | 0.210 |
Why?
|
| Aged, 80 and over | 15 | 2011 | 6767 | 0.210 |
Why?
|
| Vaginal Neoplasms | 1 | 2002 | 84 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 1214 | 0.200 |
Why?
|
| Appendix | 3 | 2011 | 31 | 0.190 |
Why?
|
| Cystadenoma | 1 | 2021 | 19 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 8 | 2013 | 359 | 0.190 |
Why?
|
| Penile Erection | 1 | 2000 | 22 | 0.190 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.180 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2000 | 30 | 0.180 |
Why?
|
| Clinical Competence | 3 | 2015 | 780 | 0.180 |
Why?
|
| Workload | 1 | 2020 | 129 | 0.170 |
Why?
|
| Urethral Diseases | 1 | 1999 | 15 | 0.170 |
Why?
|
| Ossification, Heterotopic | 1 | 1999 | 33 | 0.170 |
Why?
|
| Pelvic Bones | 1 | 1999 | 43 | 0.160 |
Why?
|
| Pelvis | 3 | 2015 | 96 | 0.160 |
Why?
|
| Phimosis | 1 | 1998 | 1 | 0.160 |
Why?
|
| Time Factors | 8 | 2014 | 5318 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 848 | 0.160 |
Why?
|
| Piperazines | 1 | 2000 | 283 | 0.160 |
Why?
|
| Biopsy | 9 | 2016 | 1181 | 0.160 |
Why?
|
| Surveys and Questionnaires | 8 | 2010 | 2609 | 0.160 |
Why?
|
| Nomograms | 2 | 2008 | 29 | 0.160 |
Why?
|
| Anastomosis, Surgical | 5 | 2011 | 273 | 0.150 |
Why?
|
| Spermine | 1 | 1998 | 21 | 0.150 |
Why?
|
| Urinary Bladder Neck Obstruction | 3 | 2008 | 21 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 1999 | 127 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2015 | 502 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 56 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2017 | 44 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 105 | 0.140 |
Why?
|
| Urinary Bladder | 2 | 2010 | 246 | 0.140 |
Why?
|
| Overweight | 2 | 2008 | 119 | 0.140 |
Why?
|
| Child | 8 | 2017 | 7139 | 0.130 |
Why?
|
| Carcinoma, Ductal | 1 | 2015 | 18 | 0.130 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2015 | 12 | 0.130 |
Why?
|
| Learning Curve | 1 | 2015 | 19 | 0.130 |
Why?
|
| Ear Canal | 1 | 2015 | 16 | 0.130 |
Why?
|
| Probability | 4 | 2010 | 353 | 0.130 |
Why?
|
| General Surgery | 2 | 2008 | 235 | 0.120 |
Why?
|
| Operative Time | 1 | 2015 | 142 | 0.120 |
Why?
|
| Logistic Models | 5 | 2011 | 1212 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2016 | 372 | 0.120 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1715 | 0.110 |
Why?
|
| Age Factors | 6 | 2013 | 1864 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 575 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 2411 | 0.110 |
Why?
|
| Organ Size | 3 | 2010 | 369 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2004 | 121 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 160 | 0.100 |
Why?
|
| Incidence | 5 | 2015 | 1591 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2015 | 426 | 0.100 |
Why?
|
| Ileum | 2 | 2010 | 160 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2011 | 92 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 251 | 0.100 |
Why?
|
| Kidney | 3 | 2009 | 1145 | 0.100 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2011 | 14 | 0.100 |
Why?
|
| Ostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
| Quality of Life | 3 | 2008 | 1662 | 0.090 |
Why?
|
| Apoptosis | 1 | 1998 | 1715 | 0.090 |
Why?
|
| Cystostomy | 1 | 2011 | 15 | 0.090 |
Why?
|
| Physicians | 2 | 2009 | 689 | 0.090 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 24 | 0.090 |
Why?
|
| Urodynamics | 3 | 2008 | 122 | 0.090 |
Why?
|
| Frozen Sections | 1 | 2010 | 49 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2012 | 2289 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 165 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 443 | 0.090 |
Why?
|
| Nephrectomy | 3 | 2007 | 293 | 0.090 |
Why?
|
| Wolffian Ducts | 1 | 2009 | 7 | 0.080 |
Why?
|
| Femoral Artery | 1 | 2009 | 83 | 0.080 |
Why?
|
| Anesthesia | 2 | 2009 | 170 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2009 | 188 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2008 | 485 | 0.080 |
Why?
|
| Reoperation | 2 | 2009 | 598 | 0.080 |
Why?
|
| Radioimmunodetection | 1 | 2008 | 13 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 293 | 0.080 |
Why?
|
| Neuromuscular Diseases | 1 | 2008 | 31 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2009 | 120 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 286 | 0.080 |
Why?
|
| Arthritis | 1 | 2008 | 47 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2009 | 169 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 682 | 0.080 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 69 | 0.070 |
Why?
|
| Prognosis | 5 | 2016 | 3770 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2008 | 56 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 251 | 0.070 |
Why?
|
| Intestines | 1 | 2010 | 416 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Medical Illustration | 1 | 2007 | 16 | 0.070 |
Why?
|
| Contracture | 1 | 2006 | 18 | 0.070 |
Why?
|
| Urologic Neoplasms | 1 | 2007 | 81 | 0.070 |
Why?
|
| Urinary Bladder Diseases | 1 | 2006 | 41 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 226 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2010 | 548 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2008 | 235 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2020 | 2857 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 2 | 1998 | 91 | 0.070 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 360 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 120 | 0.070 |
Why?
|
| United States | 2 | 2015 | 6942 | 0.060 |
Why?
|
| Female | 11 | 2010 | 45954 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2013 | 590 | 0.060 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 10 | 0.060 |
Why?
|
| Risk Factors | 5 | 2011 | 5463 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 901 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 84 | 0.060 |
Why?
|
| Obesity | 2 | 2008 | 964 | 0.050 |
Why?
|
| Survival Rate | 3 | 2015 | 1884 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2004 | 179 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2011 | 3708 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1796 | 0.050 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 634 | 0.050 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 11 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 1533 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2000 | 23 | 0.050 |
Why?
|
| Sulfones | 1 | 2000 | 45 | 0.050 |
Why?
|
| Purines | 1 | 2000 | 93 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2000 | 12 | 0.040 |
Why?
|
| Penis | 1 | 2000 | 60 | 0.040 |
Why?
|
| Leuprolide | 1 | 2000 | 35 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 240 | 0.040 |
Why?
|
| Algorithms | 2 | 2007 | 1871 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 1057 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2000 | 156 | 0.040 |
Why?
|
| Estrogens | 1 | 2000 | 201 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2012 | 181 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 1265 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1429 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 657 | 0.040 |
Why?
|
| Doxazosin | 1 | 1997 | 1 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1997 | 31 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 2008 | 90 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 412 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 397 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2017 | 83 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2010 | 778 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 244 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 205 | 0.030 |
Why?
|
| Mice, Nude | 1 | 1998 | 814 | 0.030 |
Why?
|
| Cell Survival | 1 | 1998 | 981 | 0.030 |
Why?
|
| Rats | 2 | 1998 | 4040 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 2 | 2004 | 13 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 1939 | 0.030 |
Why?
|
| Adolescent | 3 | 2011 | 9226 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 14 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 354 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 850 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 102 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 251 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 1423 | 0.030 |
Why?
|
| Infant | 1 | 1998 | 3141 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 41 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 127 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 60 | 0.020 |
Why?
|
| Spinal Dysraphism | 1 | 2010 | 19 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 122 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 84 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 1709 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 131 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 89 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 770 | 0.020 |
Why?
|
| Lymphocele | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fasciotomy | 1 | 2009 | 17 | 0.020 |
Why?
|
| Vas Deferens | 1 | 2009 | 7 | 0.020 |
Why?
|
| Aortography | 1 | 2009 | 65 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 94 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 225 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 98 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 104 | 0.020 |
Why?
|
| Urography | 1 | 2008 | 45 | 0.020 |
Why?
|
| Ureter | 1 | 2009 | 93 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2008 | 39 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 337 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2017 | 1040 | 0.020 |
Why?
|
| Mathematics | 1 | 2007 | 191 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 275 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1714 | 0.020 |
Why?
|
| Swine | 1 | 2009 | 581 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1590 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 996 | 0.020 |
Why?
|
| Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
| Mice | 2 | 1998 | 11724 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 301 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 415 | 0.020 |
Why?
|
| Animals | 3 | 2009 | 27280 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 181 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 684 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2007 | 134 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 135 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 781 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 839 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 1140 | 0.020 |
Why?
|
| Gene Library | 1 | 2004 | 133 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 188 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 299 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 470 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2000 | 60 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 1484 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1541 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2656 | 0.010 |
Why?
|
| Neomycin | 1 | 1998 | 7 | 0.010 |
Why?
|
| Karyotyping | 1 | 1998 | 253 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 116 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1998 | 261 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1998 | 615 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1998 | 1107 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 2345 | 0.000 |
Why?
|